SEC Form 4 · accession 0001225208-17-009632
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael A Mussallem
Officer — Chairman & CEO · Director
Period of report
May 10, 2017
Accepted (ET)
May 12, 2017 · 7:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 10, 2017 | M | 44,275 | $0.00 | A | 74,259 | D | |
| Common StockF1,F2 | May 10, 2017 | F | 23,103 | $110.58 | D | 51,156 | D | |
| Common StockF3 | holding | — | — | — | 123,931 | I | 401(k) | |
| Common Stock | holding | — | — | — | 676,295 | I | By Living Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance RightsF1,F2 | — | May 10, 2017 | M | 44,275 | D | — | May 31, 2017 | Common Stock | 44,275 | 0 | D |
Explanation of responses
- F1On May 8, 2014, the Reporting Person was granted a target number of shares (25,300) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.
- F2This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
- F3Shares represented on the most recent statement of Issuer's 401(k) Plan Administrator where a unitized accounting procedure is utilized to convert the equity to share equivalents.